This story is part of a series about founders and experts discovered during the Frontiers Health’s event in Berlin (Germany), where innovative healthcare professionals and disruptive entrepreneurs presented their products, services and ideas. Got a story to tell? Let us know! Email us at [email protected].
Prenuvo founder and CEO Andrew Lacy is on a mission to make early detection the new norm. With more than 170,000 scans, 25 locations across North America, and a recent $120 million Series B, Prenuvo is rapidly becoming one of the most influential healthtech scale-ups in the world.
In a healthcare system still built around reacting to symptoms, Prenuvo stands out with a simple proposition: catch disease before it catches you. Lacy believes whole-body MRI scans—once considered a luxury—should be as routine as an annual check-up. And the market is listening.
Prenuvo Is Bringing Preventive Health to the Mainstream
For decades, preventive care has lived in the shadow of traditional, symptom-driven medicine. Lacy wants to change that. Prenuvo’s one-hour whole-body MRI generates thousands of high-resolution images, giving patients a comprehensive view of their internal health—often for the first time.
Credit: Prenuvo
The approach addresses a persistent problem in diagnostics: false negatives. Many cancers and chronic diseases remain undetected until they become difficult, costly, or impossible to treat. Prenuvo’s scans aim to identify risk early, providing patients and physicians with real-world insights that drive faster, more targeted action. As a matter of fact, here is what reality TV star Kim Kardashian had to say about her experience;
“I recently did this @prenuvo scan and had to tell you all about this life saving machine. The Prenuvo full-body scan has the ability to detect cancer and diseases such as aneurysms in its earliest stages, before symptoms arise. It was like getting a MRI for an hour with no radiation. It has really saved some of my friends lives and I just wanted to share #NotAnAd.” — Kim Kardashian
And Prenuvo’s strong commitment also resonates with other A-list celebrities such as R&B superstar Tank or Paris Hilton, who proudly shared their experience with company’s whole-body MRI scan.
“People want clarity,” Lacy has said.
“They want data. They want to understand what’s happening inside their bodies before symptoms appear.”
Startup Traction: Funding, Revenue, and Global Scaling
Prenuvo’s growth looks more like a breakout tech company than a traditional healthcare provider.
- $120 million Series B raised in 2024
- $100 million annual revenue
- 25 locations across North America
- 170,000+ scans
The Series B attracted top venture firms and prominent technology leaders—an endorsement of Prenuvo’s positioning at the intersection of AI, imaging, and preventive care. New funding is accelerating global expansion and powering the next generation of its tech stack, including AI-driven diagnostic support and personalized risk-stratification tools.
Clinical Impact: Data that Gets the Industry’s Attention
Recent studies from Prenuvo—including the Polaris and Hercules initiatives—are beginning to reshape the conversation around whole-body screening.
Key findings include:
- 2.2% of asymptomatic patients were diagnosed with biopsy-confirmed cancers, often at early stages
- Clear scans correlated strongly with remaining cancer-free at 12 months
- Routine detection of non-cancerous but high-risk issues (aneurysms, brain masses, metabolic abnormalities)
For a preventive model often criticized as “too broad,” these data points are significant. They suggest Prenuvo’s scans are not only commercially popular—they may become a powerful complement to standard screening protocols.
Earning Trust in the Clinical Community
Early skepticism from clinicians has gradually shifted as more primary care providers integrate Prenuvo’s reports into patient workflows. The detailed imaging and biomarker analysis help doctors make faster, more informed decisions.
Lacy emphasizes that Prenuvo is not competing with physicians:
“We’re building tools that help doctors, not replace them. Traditional medicine and preventive imaging should work hand-in-hand.”
By positioning Prenuvo as an ally to clinicians—not an alternative—Lacy has helped the company win increasing support from health systems, integrative medicine practitioners, and forward-thinking hospital networks.
Leadership Lessons from a Savvy Serial Entrepreneur
Lacy’s path to healthtech wasn’t linear. He previously co-founded Tapulous, one of the first breakout successes on the App Store, and has held roles at McKinsey, Disney, and multiple global startups.
What carried over from tech to health?
- Resilience in the face of skepticism
- User-centered product design
- Scaling operations fast without compromising quality
Lacy now mentors founders across Europe and the US, advocating for long-term thinking in markets where regulation, inertia, and legacy systems can slow innovation.
Is Prenuvo The Future of Preventive Medicine?
Prenuvo is now positioned to be a category-defining company—part healthtech, part biotech, part data platform. Its clinics blend high-touch patient care with automation, AI, and premium clinical infrastructure.
For Lacy, the mission is bigger than building a unicorn. It’s about changing how people think about personal health.
“In 10 years, annual whole-body imaging will be as normal as annual blood work. We’re just building the infrastructure to get there.”
And with growing investor interest, strong recurring demand, and a distinctive brand already embraced by early adopters, executives, and clinicians alike, Prenuvo is making a compelling case for that future.
Key Takeaways:
- Prenuvo, led by CEO Andrew Lacy, is one of the fastest-scaling healthtech startups in North America.
- The company has raised $120M Series B, generated $100M revenue, and operates 25 clinics, with 15+ more planned globally.
- New clinical data show early cancer detection in 2.2% of asymptomatic patients, strengthening the case for whole-body MRI screening.
- Prenuvo is shaping the future of preventive health through AI, imaging innovation, and patient-centric design.
- Lacy’s evolution from tech founder to healthtech leader offers a roadmap for entrepreneurs tackling regulated, high-impact sectors.
This article was brought to you by Frontiers Health, which is one of the premier global health innovation events, with a strong focus on digital therapies, breakthrough technologies, healthcare transformation, investments, and ecosystem development. Frontiers Health is hosted and powered by EVERSANA.
Want to amplify your startup’s story? EU Startup News is your launchpad to reach startup founders, investors, and C-level execs across Europe. Discover our tailored promotional strategies such as Sponsored Articles and Partnerships. Click here to learn more or contact us directly at [email protected]. Join us, and let’s make your startup the talk of Europe!
